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James Parkinson, a London general practitioner
and political activist,1 delivered his essay on the shaking palsy in 1817 and encouraged others who "humanely employ anatomical examination" to study
the cause and nature of "this malady." Even in his
wildest fantasies I seriously doubt that he dreamed of
the extent to which his advice would be followed .
Today, in spite of a recognized incidence of only 20
cases per 100,000 persons per year; articles concerning this disorder appear in nearly every issue of
many neurology journals. The reason for this interest
is explained by the significant work that took place in
the 1960's. During that period a series of biochemical
steps leading from tyrosine to biogenically active
amines was elucidated, 3 and , further, the action of
these amines at brain synapses was convincingly hypothesized.4 Tyrosine is converted to levodopa and
then to dopamine, a neurotransmitter. Since dopamine parenterally does not enter the brain , it was
found that large doses of its precursor, levodopa,
resulted in some levodopa entering the brain, driving
the reaction in favor of more dopamine, and therefore enhancing neurotransmission. It is this concept
that has excited neurologists out of all proportion to
the frequency of Parkinson's disease in the general
population. As is now known , the pathology of Parkinson's disease lies in the substantia nigra, 5 where
neurons that ordinarily project to the striatum 6 and
transmit via dopamine are degenerating; hence the
rationale for the use of levodopa as a therapeutic
tool. As attractive as this model is, I remain suspicious that the mechanisms are far more complex
than as yet determined.
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In the management of Parkinson's disease, one
must be reasonably certain of the diagnosis. In spite
of the foregoing sophisticated biochemistry , there is
really no laboratory test for the disease, so it becomes
an entity that must be recognized on purely clinical
grounds. While the differential diagnosis can be quite
extensive and includes such rare entities as manganese poisoning, as well as such usually apparent
causes as phenothiazine intoxication or carbon monoxide sequelae, several disorders and etiologies account for most of our diagnostic problems . Although
we think of Parkinsonism as a triad of rest tremor,
rigidity , and akinesia, the onset may be with any one
of these, and if it is with tremor, the distinction from
essential tremor may be difficult. Essential tremor,
sometimes inherited as an autosomal dominant, is
occasionally seen and resembles Parkinson's disease.
The tremor is a little faster 7 and while many authors
state that it begins in an arm, as does Parkinsonism,
the head often begins to titubate soon after the
tremor begins in the hand. The onset of essential (or
familial) tremor is usually earlier than in Parkinson ' s
disease, and may even be in childhood . Its progression is slow, and it often stabilizes so that the physician may encounter a patient who recounts years of
tremor, often misdiagnosed as nervousness or Parkinsonism . The rigidity and akinesia of the latter are
never present in essential tremor. Patients with essential tremor usually display more tremor on intention
than at rest, and often find that a moderate amount
of alcohol relieves their tremor for a time. The combination of family history , long-standing symptoms,
head titubation, and absence of either rigidity or
akinesia will almost always establish the diagnosis of
essential tremor. Levodopa is of no value .
Cerebellar tremor associated with cerebellar
degeneration or other cerebellar diseases is an occa-
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sional problem. Usually the absence of rest tremor,
akinesia, and rigidity, plus other signs, for example,
truncal ataxia, will allow an easy distinction.
A variety of degenerative diseases may present
with poverty of motion and a degree of rigidity. Most
of the presenile dementias can present in this fashion,
but the predominance of the dementing element usually permits an easy differential diagnosis to be made .
Certain rare entities have been a problem, however,
one of which is progressive supranuclear palsy.8
Patients with this disease display many Parkinsonian
features, including, occasionally , involuntary movements; however, early loss of voluntary vertical gaze,
especially down gaze (with spared reflex gaze mechanisms, for example, oculovestibular reflexes) associated with conspicuous rigidity, along with a fairly
rapid course, are usually enough to permit most clinicians to arrive at the diagnosis. Levodopa is of limited, if any, benefit.
Shy-Drager syndrome (idiopathic orthostatic
hypotension )9 is another rare syndrome that has led
to some diagnostic difficulty, though usually easily
resolved . This disease reflects, to some extent, a continuum of Parkinsonism; however, the Shy-Drager
syndrome evinces a much more profound involvement of autonomic nuclei , with consequent severe orthostatic hypotension, anhidrosis, and incontinence, to the degree that the usually present
bradykinesia , rigidity, and occasional tremor are
overshadowed. Nevertheless, since orthostatic hypotension is occasionally a feature of Parkinsonism, the
distinction is sometimes a problem. Patients with
Shy-Drager syndrome respond poorly to levodopa .
A part from these syndromes, the differential
diagnosis of Parkinson's disease revolves mainly
around its etiology. Though some reputable investigators appear to feel that the encephalitis epidemic in the second and third decades of this century
accounts for most of the Parkinsonism we see, I
believe that there are multiple etiologies for the disease just as there are for hemiplegia , and that the duty
of physicians encountering patients with Parkinsonism is to attempt to elucidate the etiology.
Another area of interest that should be mentioned is genetic Parkinson's disease. 10 There is abundant evidence that familial clustering occurs in
Parkinsonism, and the finding that individuals
predisposed to developing Parkinsonian symptoms,
after treatment with phenothiazines, have a higher
incidence of family members with spontaneous Park-

inson's disease" adds further weight to the idea that
some Parkinsonism is hereditary , perhaps an inherited tyrosine hydroxylase deficiency . Nevertheless,
this is not sufficiently established to require genetic counseling, nor is hereditary Parkinsonism sufficiently different from other forms to necessitate differences in therapy. Furthermore, familial clustering
alone is insufficient evidence to rule out an infectious
etiology .
Therapeutic avenues open to the physician managing patients with Parkinson's disease can best be
summarized by considering the past, present, and
future. That the treatment of this complex disease
should change over the years is not surprising; however, that the treatment should take such profound
swings over a period of fifteen years is surprising.
The Past. Charcot is said to have noted the value
of atropine over 100 years ago. 12 Since then, and until
levodopa appeared on the scene, atropine and about
seven or eight similar drugs were the medications of
choice in Parkinson's disease . The differences in these
drugs are not great, 13 and all share, to a variable
degree, anticholinergic side effects. The peripheral
side effects of these drugs are well known; however,
centrally, drug intoxication may lead to ataxia, dysarthria, hyperthermia, and frank psychosis. The
drugs must be introduced in low dosages and in creased slowly until improvement occurs or side effects force a halt to further increment of dosage. A
modest improvement in rigidity and tremor can be
expected in 70% of patients; however, akinesia does
not respond to this treatment. 14 These drugs remain
valuable in the treatment of mild Parkinsonism and
as adjuncts to levodopa. Diphenhydramine (BenadryJ@), an antihistamine, also possesses an atropine-like action, inhibiting striatal dopamine uptake,
and is only mildly less potent than benztropine (Cogentin@).
Amphetamines enjoyed some popularity in the
past. These drugs are chemically similar to dopamine
and seem to be beneficial. Their benefits, however,
are not great enough to override their side effects, and
they are no longer used to any extent. Surgery, involving destructive lesions in several areas of the
brain, but mostly in the thalamus, enjoyed a brief
popularity in the fifties and early sixties . Useful
mainly for tremor and least valuable in akinesia,
thalamotomy procedures were often impermanent in
their benefits and had occasional failures as well as
complications, such as hemiplegia. As a result, the
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use of thalamotomy waned rapidly after the development of levodopa, and the operation is now rarely
performed for Parkinson's disease.
The Present. Long in preparation, levodopa has
been in widespread experimental use for over seven
years, and in general use for over five years. 15 First
evaluations, particularly with patients early in the
course of their disease, indicated that 70% of patients
experienced at least a 50% improvement in their
symptoms, especially akinesia and rigidity. This is a
remarkable improvement for most patients. To
achieve this goal, the d?ily dosage must be slowly
worked up to levels of 5 to 9 gm, initiated at levels of
125 to 250 mg daily, with food. Single doses should
not exceed 1.5 to 2.0 gm 13 ; hence the need for multiple
doses. The frequency of side effects is extensive. In
one series of 100 patients,1 6 49 developed abnormal
involuntary movements, 45 had gastrointestinal
problems, 30 had psychiatric manifestations, and 11
had symptomatic hypotension. Other side effects occurred less frequently. As a result of these side effects,
especially nausea, many patients never reach maximum dose levels, and treatment is discontinued because they cannot tolerate useful levels of the drug.
Part of this problem has been solved by combining
levodopa with carbidopa which is a chemical "lookalike" of levodopa that inhibits dopa-decarboxylase
extracerebrally. Thus, since 95% of levodopa is decarboxylated before it reaches the brain 17 (and is
therefore therapeutically ineffective), a combinat~on
drug allows levodopa to reach the brain in greater
amounts respective to the oral dose. The only combination currently available commercially is Sinemet
25/ 250® (Merck, Sharp, and Dohme). This product
provides a carbidopa: levodopa ratio of I: I 0, and
since carbidopa blocks at least 75% to 80% of peripheral decarboxylation of levodopa, it follows that a
Sinemet 25/250® is roughly equivalent to 1.0 gm of
oral levodopa, and in practice this seems to be the
case. In switching from levodopa to Sinemet 25/ 250®,
stop levodopa for 8 hours, then resume Sinemet 25/
250® at one-fourth the dose for levodopa. The only
real advantage to the com bi nation is the avoidance of
nausea, though a reduction in cardiac arrhythmias
and in hypotension has been reported . 17 According to
an oral communication from B. A. Huffman, in February 1976, the price of this combination drug is
15% to 20% above levodopa alone and since its chief
value is in preventing nausea, the increased expense is
hardly justified for those who tolerate, one way or the
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other, this side effect. Nonetheless, this combination
drug offers a considerable advantage to those patients
who seem unable to overcome nausea at even low
doses. In addition, and of minor importance with
out-patients, one can advance the dosage faster with
combination therapy since nausea is a minimal problem. Finally, carbidopa inhibits the action of pyridoxine in reversing levodopa action; hence ordinary
multivitamins may be used when indicated.
Other side effects that deserve special mention
are the involuntary movements and the psychologic
problems. Both can take almost any form, both are
quite common complications, and, as a rule, the development of either problem is best managed by a
reduction in dose. Both are central effects of levodopa; hence they readily occur with either levodopa
alone or in combination with carbidopa.
A final note on side effects relates to orthostatic
hypotension. This is a well-recognized side effect, and
patients on levodopa should have periodic standing
blood pressure determinations. A reduction in levodopa dose is usually required if this side effect occurs.
Other drugs may also be used to advantage with
levodopa or levodopa/carbidopa. Atropine-like
agents have already been mentioned, and while they
were never shown to provide more than a 20% improvement in symptoms, this margin may occasionally be useful along with levodopa. Amantadine,
originally an antiviral drug, has more merit as an
adjunct as well as acting alone. In one study 18 involving 48 patients, benefits of 21 % to 39% occurred
in major Parkinsonian disabilities . Side effects, consisting mainly of gastrointestinal disturbances, sleep
disturbances, and hallucinations occurred with
amantadine, but the frequency of these is low. The
dose used in this study was amantadine 200 mg daily
in divided doses. There is a tendency for benefits to
decline after several months.
Propranolol, a beta adrenergic blocking agent,
has also been used in a variety of states with
tremor 19•20 and consequently we have tried it in combination with other drugs to relieve the tremor of
Parkinson's disease. The results have not been measured, but on occasion this has seemed to be a useful
drug. Other clinicians 21 have had similar experiences.
A maximum dose of 180 to 200 mg/ day must be
approached cautiously.
One may wonder why several drugs other than
levodopa have been mentioned. Several facets of the
nature of levodopa therapy account for this. First, a
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fairly large group of patients do not respond well to
it. Second, certain patients are unable to achieve adequate levels due to side effects. And , finally, there
appears to be developing a "resis tance" to levodopa
benefit. 15 This resistance tak es several forms, but occurs in one way or another in the majority of patients.
In Barbeau's series, the percentage of patients with
excellent or good results initially was 79% and
dropped to 29% at 6 years, and 25% had stopped
levodopa. The predicted survival of severely akinetic
patients is 9.7 years, 22 thus it is suggested that
levodopa probably will not stop the progression of
Parkinsonism. Some investigators feel that there may
be a finite period of time in which levodopa is effective and therefore withold the drug until disability is
beginning to become clearly evident.
The resistance to treatment takes many forms,
but three mechanisms stand out:
I. End-of-dose akinesia. Parkinsonian symptoms recur progressively earlier following a dose.
Levodopa levels are low, and more frequent spacing
of the drug is beneficial.
2. On / Off phenomenon. Patients note periods
in which there is a sudden return of Parkinsonian
symptoms, the "Off" period. The "On" period, unfortun ately, is nearly alwa ys complicated by dyskinesias , usually appendicular and fairly distressing. In
one report, 23 29 such patients were encountered in a
population of 300 Parkinson patients. Nineteen had
been on medication more than 24 months, suggesting
that the duration of the disease or of levodopa therapy is of significance. The "Off'' period is characterized by low levodopa levels. This phenomenon is
poorly understood and its management a subject of
debate. Nevertheless, two views are worth mentioning. The first 24 embraces the concept that a hypersensitivity of the receptor occurs and suggests gradual
reduction in levodopa dose to levels of about onefifth the previous maintenance dose. The second 25
involves a reduction in presumably competing amino
acids in the diet by reducing protein intake from the
normal 1.0 to 2.0 gm/ kg to .5 gm/ kg, along with the
usual dosages of levodopa and an inhibitor. Both
methods, as well as a variety of other drug manipulations, have some merit; however, this problem remains quite serious.
3. Akinesia paradoxica . Sudden "blocking"
seems to occur, often triggered by a sudden change in
afferent sensory input (as unexpected stress), and the
patient "freezes," often falling. Blood levels of levodopa are usually high,2 1 and the theory is that there is

a sudden , unanswered demand on the noradrenalin
" drive" mech a ni sm, now depleted b y in volvement of
the locus ceruleus.21 Fortunately, this complication is
quite uncommon, since its management and pathogenesis remain uncertain.
In numerous other ways, and in spite of many
drugs, Parkinsonian patients seem to gradually lose
the benefit of medication and deteriorate after a number of years.
Several other facets of the treatment of Parkinsonism deserve special mention. A certain number
of patients develop a mild-to-moderate dementia. 26
This part of the picture does not seem to be wholly
reversible with levodopa and thus becomes part of
the overall management. Discussion of this is beyond
the scope of this paper. Another important part of
present management is physical therapy. The motivation and assista nce provided by this modality is of
inestimable value, and no experienced clinician
doubts the value of maintaining mobility in the
patient with Parkinsonism. Seriously affected patients are best cared for by facilities offering this form
of treatment.
Evaluation of the physician's treatment is quite
important, since the probability of eventual failure is
high. With any given patient, the physici a n must
establish methods of continuing patient evaluation
that include such actions as rising from a chair, handwriting, drawing whorls, and activities of daily living.17 Once clear reg ression occurs, efforts at combating this, while often futile, must be in stituted , and
a periodic semi-quantitative eva luation of the patient
is useful.
The Future. A number of pharmacologic attempts to alter Parkinson 's disease are in progress,
but most show little potential. Two that show the
greatest possibility of success presently are bromocriptine21·28 a nd apomorphine.
Bromocriptine, an ergot alkaloid containing a
lysergic-acid residue, activates dopaminergic recep. tors. The evidence cited is but a single study in which
19 patients received an optimum dose of 20 to 75 mg
daily; the original study consisted of 28 patients, but
I failed to follow directions and 8 had intolerable side
effects. Side effects, usually dose dependent, were in
every way simila r to levodopa, except for four new
reactions: erythema, edema, a nd tenderness of the
ankles; burning discomfort of the eyes; diplopia; and
frequent extrasystoles. Of the 19 who continued
bromocriptine, all but 4 were able to omit their levodopa or levodopa/ carbidopa. All noted improvement
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of Parkinsonian symptom s while on bromocriptine as
compared to a placebo, but the authors were unable
to draw a ny conclusion comparing bromocriptine
and levodopa. The drug appears to have some
promise, particularly since it obviates the necessity of
having endogenous dopa decarboxylase, whic h is also
depleted in the stria tum of Pa rkinsonian patients as
the disease progresses.
A second drug offeri ng some promise is N-propyln ora porp hine, a n analog of apomorphine having
a nephrotoxic dose far in excess o f its therapeut ic
dose.29 In the series by Cotzias e t al , 29 all 24 patients
improved, and the "On-Off' ' phe nomenon of 6
pa tients, still present on N -propylnoraporphine
alone, was abolished by co-administration of a lphamethyl dopa hydrazine. Side effects, including drugrela ted rena l toxicity in two patients, were no t uncommon, a nd further evaluation is necessa ry.
Summary. While an exha ustive review of avai lable management has not b een attempted , the frequentl y missed differential diagnoses and important
therapeutic m odalities ha ve been discussed . No treatment seem s to stay the inexorable progression o f this
disease, but several avenues offer the patient a better
quality of li fe as the disease proceeds.
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